IRIS
PERNO, CARLO-FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 149.347
AS - Asia 16.610
EU - Europa 15.252
SA - Sud America 2.666
Continente sconosciuto - Info sul continente non disponibili 1.340
AF - Africa 396
OC - Oceania 134
Totale 185.745
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 148.581
SG - Singapore 7.862
CN - Cina 2.834
DE - Germania 2.140
BR - Brasile 2.123
RU - Federazione Russa 2.119
IT - Italia 2.032
UA - Ucraina 1.872
HK - Hong Kong 1.505
SE - Svezia 1.482
VN - Vietnam 1.238
IE - Irlanda 1.233
FI - Finlandia 1.092
FR - Francia 1.018
GB - Regno Unito 787
BD - Bangladesh 735
PL - Polonia 729
KR - Corea 704
CA - Canada 398
JP - Giappone 377
IQ - Iraq 275
IN - India 231
AR - Argentina 186
ID - Indonesia 173
NL - Olanda 152
AU - Australia 131
MX - Messico 116
ZA - Sudafrica 109
BE - Belgio 107
TR - Turchia 104
AT - Austria 99
EC - Ecuador 99
ES - Italia 97
CZ - Repubblica Ceca 87
CO - Colombia 76
PH - Filippine 76
PK - Pakistan 73
IR - Iran 65
JM - Giamaica 52
VE - Venezuela 50
CL - Cile 45
UZ - Uzbekistan 43
CM - Camerun 41
CR - Costa Rica 35
KE - Kenya 35
EU - Europa 34
MA - Marocco 34
AE - Emirati Arabi Uniti 33
CH - Svizzera 33
MY - Malesia 32
SA - Arabia Saudita 32
PY - Paraguay 29
HN - Honduras 27
EG - Egitto 26
GT - Guatemala 26
NP - Nepal 25
RO - Romania 25
TN - Tunisia 25
NG - Nigeria 24
PE - Perù 23
DZ - Algeria 22
IL - Israele 22
LT - Lituania 21
TH - Thailandia 21
JO - Giordania 19
KZ - Kazakistan 19
UY - Uruguay 17
GR - Grecia 16
PT - Portogallo 16
BG - Bulgaria 15
BO - Bolivia 15
KG - Kirghizistan 15
NI - Nicaragua 15
AZ - Azerbaigian 14
TT - Trinidad e Tobago 14
SV - El Salvador 13
DK - Danimarca 12
DO - Repubblica Dominicana 12
TW - Taiwan 12
HU - Ungheria 11
ET - Etiopia 10
GH - Ghana 10
LB - Libano 10
BB - Barbados 9
BS - Bahamas 9
LK - Sri Lanka 9
OM - Oman 9
CI - Costa d'Avorio 8
DM - Dominica 8
AL - Albania 7
EE - Estonia 7
PS - Palestinian Territory 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AO - Angola 6
BY - Bielorussia 6
GD - Grenada 6
PA - Panama 6
PR - Porto Rico 6
QA - Qatar 6
RS - Serbia 6
Totale 184.318
Salva come PNG Salva come JPEG
Città #
Woodbridge 41.751
Wilmington 36.815
Houston 32.056
Singapore 4.141
Fairfield 3.941
Ashburn 3.415
Ann Arbor 3.352
San Jose 2.367
Chandler 1.981
Jacksonville 1.684
Seattle 1.670
Hong Kong 1.480
Cambridge 1.359
Council Bluffs 1.168
Dublin 1.162
Beijing 1.110
Medford 912
Santa Clara 849
Dearborn 668
Helsinki 667
Kraków 626
Los Angeles 595
New York 595
Rome 575
Moscow 534
The Dalles 513
Dallas 466
Lawrence 429
Ho Chi Minh City 375
Tokyo 314
Hanoi 299
Buffalo 288
Mülheim 270
Milan 268
São Paulo 225
San Diego 213
Menlo Park 206
Lauterbourg 191
Zhengzhou 161
Boardman 157
Munich 151
Phoenix 140
Chicago 131
Orem 128
London 122
Nuremberg 121
Jakarta 116
Denver 109
Falls Church 107
Brussels 101
Atlanta 98
North Bergen 91
Sunnyvale 90
San Francisco 88
Toronto 87
University Park 86
Columbus 84
Frankfurt am Main 79
Redwood City 79
Dong Ket 78
Baghdad 76
Brooklyn 76
Palo Alto 76
Norwalk 75
Montreal 74
Guangzhou 71
Warsaw 68
Chennai 67
Shanghai 67
Rio de Janeiro 66
Mountain View 65
Nanjing 62
Redondo Beach 62
San Mateo 62
Verona 62
Creede 59
Porto Alegre 59
Amsterdam 58
Haiphong 55
Johannesburg 54
New Orleans 52
Brno 49
Miami 47
Poplar 47
Boston 44
Saint Petersburg 44
Naples 43
Hefei 42
Vancouver 42
Vienna 41
Da Nang 40
Kunming 40
Stockholm 39
Brasília 38
Belo Horizonte 37
Lappeenranta 37
Sydney 37
Melbourne 36
Sulaymaniyah 36
Mexico City 33
Totale 154.072
Salva come PNG Salva come JPEG
Nome #
1,2,3-TRIAZOLE-[2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-RIBOFURANOSYL]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOL 2'',2''-DIOXIDE) (TSAO) ANALOGS - SYNTHESIS AND ANTI-HIV-1 ACTIVITY 1.124
Antibiotic susceptibility of vancomyin and nitrofurantoin in Staphylococcus aureus isolated from burnt patients in Sulaimaniyah, Iraqi Kurdistan 792
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 606
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 602
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 592
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 592
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 591
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 580
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 561
Progesterone and Melanoma Cells: An Old Story Suspended between Life and Death 553
KI and WU polyomaviruses and CD4+ cell counts in HIV-1-infected patients, Italy 551
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 548
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 546
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 543
A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication 542
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 542
Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4(+) T lymphocytes 541
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 537
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 530
The novel swine-origin H1N1 influenza A virus riddle: is it a domestic bird H1N1-derived virus? 527
Therapeutic strategies towards HIV-1 infection in macrophages 526
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 525
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 524
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 524
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 524
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 519
A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity 518
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 517
Thymosin alpha 1 and HIV-1: Recent advances and future perspectives 516
Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir 513
Activity of the (R)-Enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems 511
Influenza virus A (H5N1): A pandemic risk? 509
A multicenter evaluation of the Abbott RealTime HCV Genotype II assay 509
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 509
Understanding HIV compartments and reservoirs 509
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 509
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection 505
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 504
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 503
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 503
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 501
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs 501
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 501
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 500
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 500
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 499
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 499
Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro 499
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 498
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 498
Viral causes of influenza-like illness: Insight from a study during the winters 2004-2007 497
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 497
Molecular analysis based on mtLSU-rRNA and DHPS sequences of Pneumocystis jirovecii from immunocompromised and immunocompetent patients in Italy 497
HIV-1-associated dementia during HAART therapy 496
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection 495
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines 494
Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV 494
Novel drug resistance mutations in HIV: Recognition and clinical relevance 493
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 492
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 491
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 491
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 491
Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus 489
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 488
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 488
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 486
Immunomodulatory activity of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models 484
Macrophage depletion induced by clodronate-loaded erythrocytes 484
Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir 483
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 483
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 483
Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient 482
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 482
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 482
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 481
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 481
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 480
Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: Role of cells of monocyte-macrophage lineage 479
Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1) 478
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 478
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 477
Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV 477
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak 477
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 477
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 476
A case of Italian HIV-2 infection: a genetic analysis 476
Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? 476
Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. 475
Antiviral profile of HIV inhibitors in macrophages: Implications for therapy 474
Glutathione inhibits HIV replication by acting at late stages of the virus life cycle 474
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 474
The novel KI, WU, MC polyomaviruses: possible human pathogens? 473
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 473
Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients 473
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions 472
Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice 471
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 471
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 471
Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes 469
European guidelines on the clinical management of HIV-1 tropism testing 469
Totale 51.367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 416.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 416.547
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.091 0 0 0 253 210 523 206 179 764 480 232 1.244
2022/20235.987 665 415 201 716 465 1.332 426 454 482 110 498 223
2023/20242.031 267 195 142 72 258 344 88 83 55 89 35 403
2024/202511.964 417 2.601 1.198 655 364 688 1.213 536 1.077 714 1.402 1.099
2025/202620.066 1.391 873 2.267 1.592 1.531 811 2.543 2.703 2.220 1.866 1.174 1.095
2026/20276.258 1.065 1.112 3.479 602 0 0 0 0 0 0 0 0
Totale 185.745